

Message

From: isabelle.emery [REDACTED]
Sent: 12/17/2003 11:23:17 AM
To: Gordon Francis [REDACTED]; Maria Lopez-Bresnahan [REDACTED]
 [REDACTED]; Alain Munafo [REDACTED]; Alain
 Micaloff [REDACTED]; Samir Shah [REDACTED]
 [REDACTED]; Nazih Ammoury [REDACTED]; Amer
 Jaber [REDACTED]; Germano Oberto [REDACTED]
 [REDACTED]; Isabella Cei Martini [REDACTED]
 [REDACTED]; Alison Ernst [REDACTED]; Paola Ricci
 [REDACTED]; yogesh.dandike [REDACTED]; stephen_marcus [REDACTED]
CC: Mario Maio [REDACTED]; Stuart McMillan [REDACTED]
 [REDACTED]; Susan Sangster [REDACTED]; Jill Hillier
 [REDACTED]; Francois Maillard [REDACTED];
 david.browr [REDACTED]; kate.bentley [REDACTED]; Dodie Frank [REDACTED]
 [REDACTED]; Turid Ekengren [REDACTED];
 Lan Nguyen [REDACTED]
Subject: Cladribine - draft for BD [REDACTED]
Attachments: Clabribine Briefing Document 17 Dec 2003.doc; [REDACTED]

Dear All,

Please find hereunder the first draft of the **Briefing document** [REDACTED].

In the table below, the names of the reviewers is indicated with section(s) to be reviewed.

[REDACTED]

[REDACTED]

[REDACTED]


[REDACTED]


[REDACTED]

Review Brief

Document:	Briefing document [REDACTED]
------------------	------------------------------

Merck 2078

	 Clabribine Briefing Document 17 Dec 2003.doc
Date:	17 December 2003
From:	I. Emery
<u>Review Instructions</u>	
Reviewers 1	A. Jaber, Y. Dandiker
Sections to be reviewed:	CMC section (Section 2)
[REDACTED]	[REDACTED]
Reviewers 2	Germano Oberto, Steve Marcus
Sections to be reviewed:	Nonclinical section (Section 3)
[REDACTED]	[REDACTED]
Reviewers 3	Alain Munafo, Steve Marcus
Sections to be reviewed:	PK and PD human info (Section 4.2)
[REDACTED]	[REDACTED]
Reviewers 4	Maria Lopez-Bresnahan, Gordon Francis, Alain Micaloff, Samir Shah, Nazih Ammoury, Isabella Cei Martini, Alison Ernst, Paola Ricci, Steve Marcus
Sections to be reviewed:	All
[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]



Thank you in advance for your action.

Kind regards.

Isabelle Emery



Cladribine

(2-chloro-6-amino-9-(2-deoxy- β -D-erythropento-furanosyl) purine)

Briefing Document

December 2003

TABLE OF CONTENTS

█	
█	
█ █ █	
█ █ █ █ █	
█ █	

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.